Want to join the conversation?
$VRTX has begun marketing cystic fibrosis drug Orkambi in the U.S. and will recognize its first net product revenue from Orkambi in 3Q15. $VRTX believes that there currently are about 8,500 patients in the U.S. who are eligible for treatment with Orkambi.
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?
$YHOO is reporting today after market close. Nobody cares about this stock.